Liquidia Corporation
LQDAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jun 1, 2026
Scan Results
Daily timeframeLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. Valued at $5.50B, LQDA is a mid-cap name in its sector. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Market Cap
$5.50B
Beta
0.42
P/E (TTM)
363.88
P/E (Fwd)
11.10
EPS (TTM)
$0.17
EPS (Fwd)
$5.57
ROE
28.2%
ROA
9.0%
Cash
$222.8M
Total Debt
$184.8M
Free CF
$9.6M
52W Change
266.7%
Annual Financials
Cash vs Debt
Liquidia Corporation holds $222.8M in cash against $184.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $9.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 28.2% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 9.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $15.9M (2022) to $158.3M (2025), reflecting a 894% increase over the period.
With a beta below 0.7, Liquidia Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing LQDA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.